Silexion Therapeutics Statistics
Total Valuation
SLXN has a market cap or net worth of $9.44 million. The enterprise value is $2.22 million.
Important Dates
The last earnings date was Wednesday, November 12, 2025, before market open.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
SLXN has 3.13 million shares outstanding.
| Current Share Class | 3.13M |
| Shares Outstanding | 3.13M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +947.99% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.92% |
| Float | 3.00M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.35 |
| P/TBV Ratio | 1.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.97, with a Debt / Equity ratio of 0.29.
| Current Ratio | 3.97 |
| Quick Ratio | 3.32 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -338.00 |
Financial Efficiency
Return on equity (ROE) is -771.23% and return on invested capital (ROIC) is -130.60%.
| Return on Equity (ROE) | -771.23% |
| Return on Assets (ROA) | -77.60% |
| Return on Invested Capital (ROIC) | -130.60% |
| Return on Capital Employed (ROCE) | -103.38% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$660,500 |
| Employee Count | 14 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, SLXN has paid $4,000 in taxes.
| Income Tax | 4,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -92.84% in the last 52 weeks. The beta is -0.06, so SLXN's price volatility has been lower than the market average.
| Beta (5Y) | -0.06 |
| 52-Week Price Change | -92.84% |
| 50-Day Moving Average | 3.20 |
| 200-Day Moving Average | 9.99 |
| Relative Strength Index (RSI) | 52.65 |
| Average Volume (20 Days) | 65,059 |
Short Selling Information
The latest short interest is 91,327, so 2.92% of the outstanding shares have been sold short.
| Short Interest | 91,327 |
| Short Previous Month | 145,745 |
| Short % of Shares Out | 2.92% |
| Short % of Float | 3.05% |
| Short Ratio (days to cover) | 1.59 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -9.13M |
| Pretax Income | -9.24M |
| Net Income | -9.25M |
| EBITDA | -9.13M |
| EBIT | -9.13M |
| Earnings Per Share (EPS) | -$16.23 |
Full Income Statement Balance Sheet
The company has $9.24 million in cash and $2.03 million in debt, giving a net cash position of $7.22 million or $2.31 per share.
| Cash & Cash Equivalents | 9.24M |
| Total Debt | 2.03M |
| Net Cash | 7.22M |
| Net Cash Per Share | $2.31 |
| Equity (Book Value) | 6.98M |
| Book Value Per Share | 2.23 |
| Working Capital | 8.27M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$10.73 million and capital expenditures -$7,000, giving a free cash flow of -$10.74 million.
| Operating Cash Flow | -10.73M |
| Capital Expenditures | -7,000 |
| Free Cash Flow | -10.74M |
| FCF Per Share | -$3.43 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SLXN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -97.93% |
| FCF Yield | -113.70% |
Analyst Forecast
The average price target for SLXN is $75.00, which is 2,383.44% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $75.00 |
| Price Target Difference | 2,383.44% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -57.15% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 29, 2025. It was a reverse split with a ratio of 1:15.
| Last Split Date | Jul 29, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |